{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:10:33Z","timestamp":1768813833084,"version":"3.49.0"},"reference-count":146,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100001321","name":"National Research South Africa","doi-asserted-by":"publisher","award":["123375"],"award-info":[{"award-number":["123375"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Since the discovery of insulin, continuous developments of this peptide have led to better management of diabetes mellitus, thus leading to a decrease in diabetes-related mortality. Despite these developments, we have seen an increase in diabetes cases, which has further necessitated more innovative methods for diabetes management. The subcutaneous administration of insulin remains the mainstay therapy for type 1 diabetes mellitus. However, despite the availability of insulin analogues with improved pharmacokinetics, challenges with conventional administration exist. The challenges associated with insulin injections include hypoglycaemic episodes, needle phobia, and injection-site inflammation, which all have been reported to reduce patient compliance. Ongoing research on diabetes management strives to develop therapies that provide improved glycaemic control with minimal side effects. In part, for these reasons, we have seen an increase in the search and development of alternative insulin delivery systems that are envisaged to circumvent the shortfalls associated with the conventional administration route. Several alternative drug delivery systems, such as oral, pulmonary, buccal, nasal, and transdermal, have been explored in the last century. These efforts have not been without victory, as we have seen the emergence of pulmonary (Exubera and Afrezza) and buccal insulin delivery systems licenced for therapeutic use. Despite the success seen in these two systems, their marketability and popularity have been severely compromised due to reported safety concerns. Although oral insulin delivery has always shown promise in the past decades; however, it was only limited to preclinical trials. The main challenge associated with this delivery route is poor bioavailability, which necessitates high insulin concentration to be administered. Due to recent developments, oral insulin has reached phase 3 clinical trials. It is believed that patients would prefer oral insulin as their preference is often observed for oral antidiabetics over injected ones. In the last decade, transdermal insulin has also gained interest, where delivery of insulin with a concomitant reduction in blood glucose concentration has been demonstrated in vivo. However, at present, there are no clinical studies that have reported the efficacy of transdermal insulin administration. With technological advancement, there is a potential to develop yet another insulin delivery system that would likely enter the markets. As these novel delivery systems have been found to be effective, emerging competing products should be welcome and appreciated.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1567201819666220531101203","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T05:17:56Z","timestamp":1654060676000},"page":"656-668","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Celebrating a Century of Insulin Discovery: A Critical Appraisal of the Emerging Alternative Insulin Delivery Systems"],"prefix":"10.2174","volume":"20","author":[{"given":"Ntethelelo","family":"Sibiya","sequence":"first","affiliation":[{"name":"Pharmacology Division, Faculty of Pharmacy, Rhodes University, Makhanda, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonisiwe","family":"Mbatha","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu Natal Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phikelelani","family":"Ngubane","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu Natal Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andile","family":"Khathi","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu Natal Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","volume":"94","author":"Whiting D.R.","year":"2011","unstructured":"Whiting D.R.; Guariguata L.; Weil C.; Shaw J.; IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011,94(3),311-321","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1744-8603-5-9","volume":"5","author":"Young F.","year":"2009","unstructured":"Young F.; Critchley J.A.; Johnstone L.K.; Unwin N.C.; A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. Global Health 2009,5(1),9","journal-title":"Global Health"},{"key":"ref=3","author":"Inzucchi S.E.","year":"2011","unstructured":"Inzucchi S.E.; Sherwin R.S.; Type 2 diabetes mellitus. In: Cecil Medicine, 24th Ed; Saunders Elsevier: Philadelphia, PA, 2011"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2337\/diabetes.52.3.581","volume":"52","author":"Robertson R.P.","year":"2003","unstructured":"Robertson R.P.; Harmon J.; Tran P.O.; Tanaka Y.; Takahashi H.; Glucose toxicity in \u03b2-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003,52(3),581-587","journal-title":"Diabetes"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1172\/JCI10582","volume":"106","author":"Pessin J.E.","year":"2000","unstructured":"Pessin J.E.; Saltiel A.R.; Signaling pathways in insulin action: Molecular targets of insulin resistance. J Clin Invest 2000,106(2),165-169","journal-title":"J Clin Invest"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrd.2015.36","volume":"15","author":"Zaykov A.N.","year":"2016","unstructured":"Zaykov A.N.; Mayer J.P.; DiMarchi R.D.; Pursuit of a perfect insulin. Nat Rev Drug Discov 2016,15(6),425-439","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/(SICI)1096-9136(199711)14:11<919:AID-DIA456>3.0.CO;2-A","volume":"14","author":"Egger M.","year":"1997","unstructured":"Egger M.; Davey Smith G.; Stettler C.; Diem P.; Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: A meta-analysis. Diabet Med 1997,14(11),919-928","journal-title":"Diabet Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1152\/physiologyonline.2000.15.2.72","volume":"15","author":"Rorsman P.","year":"2000","unstructured":"Rorsman P.; Eliasson L.; Renstr\u00f6m E.; Gromada J.; Barg S.; G\u00f6pel S.; The cell physiology of biphasic insulin secretion. News Physiol Sci 2000,15(2),72-77","journal-title":"News Physiol Sci"},{"key":"ref=9","first-page":"20","volume":"28","author":"Matthews D.R.","year":"1985","unstructured":"Matthews D.R.; Connolly A.A.; Holman R.R.; Turner R.C.; Physiology of insulin secretion: Problems of quantity and timing. Neth J Med 1985,28(Suppl. 1),20-24","journal-title":"Neth J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/jdi.12094","volume":"4","author":"Komatsu M.","year":"2013","unstructured":"Komatsu M.; Takei M.; Ishii H.; Sato Y.; Glucose-stimulated insulin secretion: A newer perspective. J Diabetes Investig 2013,4(6),511-516","journal-title":"J Diabetes Investig"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10534-005-3685-y","volume":"18","author":"Dunn M.F.","year":"2005","unstructured":"Dunn M.F.; Zinc-ligand interactions modulate assembly and stability of the insulin hexamer - a review. Biometals 2005,18(4),295-303","journal-title":"Biometals"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e3882","DOI":"10.1210\/clinem\/dgaa522","volume":"105","author":"Huber M.P.","year":"2020","unstructured":"Huber M.P.; Zelnick L.R.; Utzschneider K.M.; Kahn S.E.; de Boer I.H.; Kestenbaum B.R.; Tubular secretory clearance is associated with whole-body insulin clearance. J Clin Endocrinol Metab 2020,105(11),e3882-e3891","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2078-7685.197963","volume":"2","author":"Kumria R.","year":"2011","unstructured":"Kumria R.; Goomber G.; Emerging trends in insulin delivery: Buccal route. J Diabetol 2011,2(1),1-9","journal-title":"J Diabetol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1055\/s-0029-1212143","volume":"107","author":"Brandenburg D.","year":"1999","unstructured":"Brandenburg D.; Insulin-structure, function, design. Exp Clin Endocrin Diabetes 1999,107(Suppl. 2),S6-S12","journal-title":"Exp Clin Endocrin Diabetes"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4161\/isl.24590","volume":"5","author":"Sanlioglu A.D.","year":"2013","unstructured":"Sanlioglu A.D.; Altunbas H.A.; Balci M.K.; Griffith T.S.; Sanlioglu S.; Clinical utility of insulin and insulin analogs. Islets 2013,5(2),67-78","journal-title":"Islets"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/pro.5560051215","volume":"5","author":"Bakaysa D.L.","year":"1996","unstructured":"Bakaysa D.L.; Radziuk J.; Havel H.A.; Brader M.L.; Li S.; Dodd S.W.; Beals J.M.; Pekar A.H.; Brems D.N.; Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: Dissociation of a protein-ligand complex. Protein Sci 1996,5(12),2521-2531","journal-title":"Protein Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5694\/j.1326-5377.2003.tb05628.x","volume":"179","author":"Couper J.J.","year":"2003","unstructured":"Couper J.J.; Prins J.B.; 2: Recent advances in therapy of diabetes. Med J Aust 2003,179(8),441-447","journal-title":"Med J Aust"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrendo.2017.39","volume":"13","author":"Mathieu C.","year":"2017","unstructured":"Mathieu C.; Gillard P.; Benhalima K.; Insulin analogues in type 1 diabetes mellitus: Getting better all the time. Nat Rev Endocrinol 2017,13(7),385-399","journal-title":"Nat Rev Endocrinol"},{"key":"ref=19","first-page":"213","volume":"2","author":"Poon K.","year":"2010","unstructured":"Poon K.; King A.B.; Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc Patient Saf 2010,2,213-223","journal-title":"Drug Healthc Patient Saf"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2147\/IJGM.S26889","volume":"4","author":"Morello C.M.","year":"2011","unstructured":"Morello C.M.; Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int J Gen Med 2011,4,827-835","journal-title":"Int J Gen Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4093\/dmj.2019.0121","volume":"43","author":"Cappon G.","year":"2019","unstructured":"Cappon G.; Vettoretti M.; Sparacino G.; Facchinetti A.; Continuous glucose monitoring sensors for diabetes management: A review of technologies and applications. Diabetes Metab J 2019,43(4),383-397","journal-title":"Diabetes Metab J"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"794363","DOI":"10.3389\/fphar.2021.794363","volume":"12","author":"Mardare I.","year":"2022","unstructured":"Mardare I.; Campbell S.M.; Meyer J.C.; Sefah I.A.; Massele A.; Godman B.; Enhancing choices regarding the administration of insulin among patients with diabetes requiring insulin across countries and implications for future care. Front Pharmacol 2022,12,794363","journal-title":"Front Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2337\/cd19-0008","volume":"38","author":"Grunberger G.","year":"2020","unstructured":"Grunberger G.; Sze D.; Ermakova A.; Sieradzan R.; Oliveria T.; Miller E.M.; Treatment intensification with insulin pumps and other technologies in patients with type 2 diabetes: Results of a physician survey in the United States. Clin Diabetes 2020,38(1),47-55","journal-title":"Clin Diabetes"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13947","volume":"22","author":"Grunberger G.","year":"2020","unstructured":"Grunberger G.; Bhargava A.; Ly T.; Zisser H.; Ilag L.L.; Malone J.; Fan L.; Zhang S.; Johnson J.; Human regular U-500 insulin via continuous subcutaneous insulin infusion via multiple daily injections in adults with type 2 diabetes: The VIVID study. Diabetes Obes Metab 2020,22(3),434-441","journal-title":"Diabetes Obes Metab"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1463-1326.2007.00802.x","volume":"10","author":"Iglesias P.","year":"2008","unstructured":"Iglesias P.; D\u00edez J.J.; Insulin therapy in renal disease. Diabetes Obes Metab 2008,10(10),811-823","journal-title":"Diabetes Obes Metab"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/0145721709345773","volume":"35","author":"Rubin R.R.","year":"2009","unstructured":"Rubin R.R.; Peyrot M.; Kruger D.F.; Travis L.B.; Barriers to insulin injection therapy: Patient and health care provider perspectives. Diabetes Educ 2009,35(6),1014-1022","journal-title":"Diabetes Educ"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00128071-200708010-00003","volume":"8","author":"Radermecker R.P.","year":"2007","unstructured":"Radermecker R.P.; Pi\u00e9rard G.E.; Scheen A.J.; Lipodystrophy reactions to insulin: Effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol 2007,8(1),21-28","journal-title":"Am J Clin Dermatol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1440-1754.2006.00911.x","volume":"42","author":"Mamoulakis D.","year":"2006","unstructured":"Mamoulakis D.; Bitsori M.; Galanakis E.; Raissaki M.; Kalmanti M.; Insulin-induced oedema in children and adolescents. J Paediatr Child Health 2006,42(10),655-657","journal-title":"J Paediatr Child Health"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11892-017-0955-3","volume":"17","author":"Dongerkery S.P.","year":"2017","unstructured":"Dongerkery S.P.; Schroeder P.R.; Shomali M.E.; Insulin and its cardiovascular effects: What is the current evidence? Curr Diab Rep 2017,17(12),120","journal-title":"Curr Diab Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S1461-5347(00)00247-9","volume":"3","author":"Sastry S.V.","year":"2000","unstructured":"Sastry S.V.; Nyshadham J.R.; Fix J.A.; Recent technological advances in oral drug delivery - a review. Pharm Sci Technol Today 2000,3(4),138-145","journal-title":"Pharm Sci Technol Today"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/polym11091380","volume":"11","author":"Mansoor S.","year":"2019","unstructured":"Mansoor S.; Kondiah P.P.D.; Choonara Y.E.; Pillay V.; Polymer-based nanoparticle strategies for insulin delivery. Polymers (Basel) 2019,11(9),1380","journal-title":"Polymers (Basel)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","volume":"19","author":"Hamman J.H.","year":"2005","unstructured":"Hamman J.H.; Enslin G.M.; Kotz\u00e9 A.F.; Oral delivery of peptide drugs: Barriers and developments. BioDrugs 2005,19(3),165-177","journal-title":"BioDrugs"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1211\/0022357991776976","volume":"51","author":"Uchiyama T.","year":"1999","unstructured":"Uchiyama T.; Sugiyama T.; Quan Y.S.; Kotani A.; Okada N.; Fujita T.; Muranishi S.; Yamamoto A.; Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: Their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-\u03b2-D-maltopyranoside. J Pharm Pharmacol 1999,51(11),1241-1250","journal-title":"J Pharm Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0168-3659(99)00247-3","volume":"65","author":"Carino G.P.","year":"2000","unstructured":"Carino G.P.; Jacob J.S.; Mathiowitz E.; Nanosphere based oral insulin delivery. J Control Release 2000,65(1-2),261-269","journal-title":"J Control Release"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fphar.2020.00524","volume":"11","author":"Hua S.","year":"2020","unstructured":"Hua S.; Advances in oral drug delivery for regional targeting in the gastrointestinal tract-influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol 2020,11,524","journal-title":"Front Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cis.2018.02.002","volume":"253","author":"McClements D.J.","year":"2018","unstructured":"McClements D.J.; Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: A review. Adv Colloid Interface Sci 2018,253,1-22","journal-title":"Adv Colloid Interface Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/children7120307","volume":"7","author":"Dan N.","year":"2020","unstructured":"Dan N.; Samanta K.; Almoazen H.; An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics. Children (Basel) 2020,7(12),307","journal-title":"Children (Basel)"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","volume":"20","author":"Mahato R.I.","year":"2003","unstructured":"Mahato R.I.; Narang A.S.; Thoma L.; Miller D.D.; Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 2003,20(2-3),153-214","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.reactfunctpolym.2010.10.002","volume":"71","author":"Park K.","year":"2011","unstructured":"Park K.; Kwon I.C.; Park K.; Oral protein delivery: Current status and future prospect. React Funct Polym 2011,71(3),280-287","journal-title":"React Funct Polym"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jphp.12852","volume":"70","author":"Gedawy A.","year":"2018","unstructured":"Gedawy A.; Martinez J.; Al-Salami H.; Dass C.R.; Oral insulin delivery: Existing barriers and current counter-strategies. J Pharm Pharmacol 2018,70(2),197-213","journal-title":"J Pharm Pharmacol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1023\/A:1015930821648","volume":"5","author":"Aungst B.J.","year":"1988","unstructured":"Aungst B.J.; Rogers N.J.; Site dependence of absorption-promoting actions of laureth-9, Na salicylate, Na2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm Res 1988,5(5),305-308","journal-title":"Pharm Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1023\/A:1018997101542","volume":"11","author":"Shao Z.","year":"1994","unstructured":"Shao Z.; Li Y.; Chermak T.; Mitra A.K.; Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of \u03b2-cyclodextrin derivatives on \u03b1-chymotryptic degradation and enteral absorption of insulin in rats. Pharm Res 1994,11(8),1174-1179","journal-title":"Pharm Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/joe.0.1640001","volume":"164","author":"Musabayane C.T.","year":"2000","unstructured":"Musabayane C.T.; Munjeri O.; Bwititi P.; Osim E.E.; Orally administered, insulin-loaded amidated pectin hydrogel beads sustain plasma concentrations of insulin in streptozotocin-diabetic rats. J Endocrinol 2000,164(1),1-6","journal-title":"J Endocrinol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e03650","DOI":"10.1016\/j.heliyon.2020.e03650","volume":"6","author":"Momoh M.A.","year":"2020","unstructured":"Momoh M.A.; Franklin K.C.; Agbo C.P.; Ugwu C.E.; Adedokun M.O.; Anthony O.C.; Chidozie O.E.; Okorie A.N.; Microemulsion-based approach for oral delivery of insulin: Formulation design and characterization. Heliyon 2020,6(3),e03650","journal-title":"Heliyon"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijpharm.2018.02.045","volume":"542","author":"Czuba E.","year":"2018","unstructured":"Czuba E.; Diop M.; Mura C.; Schaschkow A.; Langlois A.; Bietiger W.; Neidl R.; Virciglio A.; Auberval N.; Julien-David D.; Maillard E.; Frere Y.; Marchioni E.; Pinget M.; Sigrist S.; Oral insulin delivery, the challenge to increase insulin bioavailability: Influence of surface charge in nanoparticle system. Int J Pharm 2018,542(1-2),47-55","journal-title":"Int J Pharm"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4155\/TDE.15.47","volume":"6","author":"Lopes M.","year":"2015","unstructured":"Lopes M.; Sim\u00f5es S.; Veiga F.; Sei\u00e7a R.; Ribeiro A.; Why most oral insulin formulations do not reach clinical trials. Ther Deliv 2015,6(8),973-987","journal-title":"Ther Deliv"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejpb.2012.10.003","volume":"83","author":"Antunes F.","year":"2013","unstructured":"Antunes F.; Andrade F.; Ara\u00fajo F.; Ferreira D.; Sarmento B.; Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 2013,83(3),427-435","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1039\/c2lc40139h","volume":"12","author":"Chu M.K.","year":"2012","unstructured":"Chu M.K.; Chen J.; Gordijo C.R.; Chiang S.; Ivovic A.; Koulajian K.; Giacca A.; Wu X.Y.; Sun Y.; In vitro and in vivo testing of glucose-responsive insulin-delivery microdevices in diabetic rats. Lab Chip 2012,12(14),2533-2539","journal-title":"Lab Chip"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","volume":"52","author":"Hemkens L.G.","year":"2009","unstructured":"Hemkens L.G.; Grouven U.; Bender R.; G\u00fcnster C.; Gutschmidt S.; Selke G.W.; Sawicki P.T.; Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009,52(9),1732-1744","journal-title":"Diabetologia"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","volume":"7","author":"Halberg I.B.","year":"2019","unstructured":"Halberg I.B.; Lyby K.; Wassermann K.; Heise T.; Zijlstra E.; Plum-M\u00f6rschel L.; Efficacy and safety of oral basal insulin via subcutaneous insulin glargine in type 2 diabetes: A randomised, double-blind, phase 2 trial. Lancet Diabetes Endocrinol 2019,7(3),179-188","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2017.17070","volume":"318","author":"Krischer J.P.","year":"2017","unstructured":"Krischer J.P.; Schatz D.A.; Bundy B.; Skyler J.S.; Greenbaum C.J.; Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: A randomized clinical trial. JAMA 2017,318(19),1891-1902","journal-title":"JAMA"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s40262-019-00772-2","volume":"58","author":"Halberg I.B.","year":"2019","unstructured":"Halberg I.B.; Lyby K.; Wassermann K.; Heise T.; Plum-M\u00f6rschel L.; Zijlstra E.; The effect of food intake on the pharmacokinetics of oral basal insulin: A randomised crossover trial in healthy male subjects. Clin Pharmacokinet 2019,58(11),1497-1504","journal-title":"Clin Pharmacokinet"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","volume":"10","author":"Fleseriu M.","year":"2022","unstructured":"Fleseriu M.; Dreval A.; Bondar I.; Vagapova G.; Macut D.; Pokramovich Y.G.; Molitch M.E.; Leonova N.; Raverot G.; Grineva E.; Poteshkin Y.E.; Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: A phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2022,10(2),102-111","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12325-020-01561-1","volume":"38","author":"Igarashi A.","year":"2021","unstructured":"Igarashi A.; Bekker Hansen B.; Langer J.; Tavella F.; Collings H.; Davies N.; Wyn R.; Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: A discrete choice experiment. Adv Ther 2021,38(1),721-738","journal-title":"Adv Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2174\/1381612013397384","volume":"7","author":"Heinemann L.","year":"2001","unstructured":"Heinemann L.; Pf\u00fctzner A.; Heise T.; Alternative routes of administration as an approach to improve insulin therapy: Update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001,7(14),1327-1351","journal-title":"Curr Pharm Des"},{"key":"ref=56","first-page":"395","volume":"14","author":"Yu J.","year":"1997","unstructured":"Yu J.; Chien Y.W.; Pulmonary drug delivery: Physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst 1997,14(4),395-453","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/rr58","volume":"2","author":"Agu R.U.","year":"2001","unstructured":"Agu R.U.; Ugwoke M.I.; Armand M.; Kinget R.; Verbeke N.; The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001,2(4),198-209","journal-title":"Respir Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17425247.2021.1825375","volume":"18","author":"Maher S.","year":"2021","unstructured":"Maher S.; Geoghegan C.; Brayden D.J.; Intestinal permeation enhancers to improve oral bioavailability of macromolecules: Reasons for low efficacy in humans. Expert Opin Drug Deliv 2021,18(2),273-300","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/13543776.2019.1679767","volume":"29","author":"El-Hammadi M.M.","year":"2019","unstructured":"El-Hammadi M.M.; Arias J.L.; An update on liposomes in drug delivery: A patent review (2014-2018). Expert Opin Ther Pat 2019,29(11),891-907","journal-title":"Expert Opin Ther Pat"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2174\/1389201020666191011152248","volume":"21","author":"Liu H.","year":"2020","unstructured":"Liu H.; Shan X.; Yu J.; Li X.; Hu L.; Recent advances in inhaled formulations and pulmonary insulin delivery systems. Curr Pharm Biotechnol 2020,21(3),180-193","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/10837450.2020.1832117","volume":"26","author":"Hadiya S.","year":"2021","unstructured":"Hadiya S.; Radwan R.; Zakaria M.; El-Sherif T.; Hamad M.A.; Elsabahy M.; Nanoparticles integrating natural and synthetic polymers for in vivo insulin delivery. Pharm Dev Technol 2021,26(1),30-40","journal-title":"Pharm Dev Technol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/jamp.2011.0876","volume":"24","author":"Zarogoulidis P.","year":"2011","unstructured":"Zarogoulidis P.; Papanas N.; Kouliatsis G.; Spyratos D.; Zarogoulidis K.; Maltezos E.; Inhaled insulin: Too soon to be forgotten? J Aerosol Med Pulm Drug Deliv 2011,24(5),213-223","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/03639040600712862","volume":"32","author":"Mahesh Kumar T.","year":"2006","unstructured":"Mahesh Kumar T.; Misra A.; Formulation and evaluation of insulin dry powder for inhalation. Drug Dev Ind Pharm 2006,32(6),677-686","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1089\/dia.2007.0222","volume":"9","author":"Harper N.J.","year":"2007","unstructured":"Harper N.J.; Gray S.; De Groot J.; Parker J.M.; Sadrzadeh N.; Schuler C.; Schumacher J.D.; Seshadri S.; Smith A.E.; Steeno G.S.; Stevenson C.L.; Taniere R.; Wang M.; Bennett D.B.; The design and performance of the exubera pulmonary insulin delivery system. Diabetes Technol Ther 2007,9(Suppl. 1),S16-S27","journal-title":"Diabetes Technol Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1089\/dia.2005.7.896","volume":"7","author":"White S.","year":"2005","unstructured":"White S.; Bennett D.B.; Cheu S.; Conley P.W.; Guzek D.B.; Gray S.; Howard J.; Malcolmson R.; Parker J.M.; Roberts P.; Sadrzadeh N.; Schumacher J.D.; Seshadri S.; Sluggett G.W.; Stevenson C.L.; Harper N.J.; EXUBERA: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005,7(6),896-906","journal-title":"Diabetes Technol Ther"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1345\/aph.1P055","volume":"44","author":"Neumiller J.J.","year":"2010","unstructured":"Neumiller J.J.; Campbell R.K.; Wood L.D.; A review of inhaled technosphere insulin. Ann Pharmacother 2010,44(7-8),1231-1239","journal-title":"Ann Pharmacother"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.2337\/diacare.27.10.2356","volume":"27","author":"Hollander P.A.","year":"2004","unstructured":"Hollander P.A.; Blonde L.; Rowe R.; Mehta A.E.; Milburn J.L.; Hershon K.S.; Chiasson J.L.; Levin S.R.; Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004,27(10),2356-2362","journal-title":"Diabetes Care"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1345\/aph.1E522","volume":"39","author":"Odegard P.S.","year":"2005","unstructured":"Odegard P.S.; Capoccia K.L.; Inhaled insulin. Exubera Ann Pharmacother 2005,39(5),843-853","journal-title":"Exubera Ann Pharmacother"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nbt1207-1331","volume":"25","author":"Mack G.S.","year":"2007","unstructured":"Mack G.S.; Pfizer dumps Exubera. Nat Biotechnol 2007,25(12),1331-1332","journal-title":"Nat Biotechnol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1365-2125.2008.03122.x","volume":"65","author":"Fountaine R.","year":"2008","unstructured":"Fountaine R.; Milton A.; Checchio T.; Wei G.; Stolar M.; Teeter J.; Jaeger R.; Fryburg D.; Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. Br J Clin Pharmacol 2008,65(6),864-870","journal-title":"Br J Clin Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/dia.2009.0062","volume":"11","author":"Rosenstock J.","year":"2009","unstructured":"Rosenstock J.; Cefalu W.T.; Hollander P.A.; Klioze S.S.; Reis J.; Duggan W.T.; Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: A 3-year randomized controlled trial. Diabetes Technol Ther 2009,11(11),697-705","journal-title":"Diabetes Technol Ther"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1586\/17446651.2.3.313","volume":"2","author":"Norwood P.","year":"2007","unstructured":"Norwood P.; Inhaled insulin: A clinical perspective with emphasis on EXUBERA\u00ae. Expert Rev Endocrinol Metab 2007,2(3),313-320","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2146\/ajhp140540","volume":"72","author":"Ledet G.","year":"2015","unstructured":"Ledet G.; Graves R.A.; Bostanian L.A.; Mandal T.K.; A second-generation inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 2015,72(14),1181-1187","journal-title":"Am J Health Syst Pharm"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1177\/0192623320960420","volume":"49","author":"Greene S.F.","year":"2021","unstructured":"Greene S.F.; Nikula K.J.; Poulin D.; McInally K.; Reynolds J.A.; Long-term nonclinical pulmonary safety assessment of Afrezza, a novel insulin inhalation powder. Toxicol Pathol 2021,49(2),334-348","journal-title":"Toxicol Pathol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13300-020-00831-z","volume":"11","author":"Kesavadev J.","year":"2020","unstructured":"Kesavadev J.; Saboo B.; Krishna M.B.; Krishnan G.; Evolution of insulin delivery devices: From syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther 2020,11(6),1251-1269","journal-title":"Diabetes Ther"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1463-1326.2009.01039.x","volume":"11","author":"Rave K.","year":"2009","unstructured":"Rave K.; Potocka E.; Heinemann L.; Heise T.; Boss A.H.; Marino M.; Costello D.; Chen R.; Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab 2009,11(7),715-720","journal-title":"Diabetes Obes Metab"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jconrel.2015.07.025","volume":"215","author":"Al-Tabakha M.M.","year":"2015","unstructured":"Al-Tabakha M.M.; Future prospect of insulin inhalation for diabetic patients: The case of Afrezza via Exubera. J Control Release 2015,215,25-38","journal-title":"J Control Release"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2337\/diaspect.29.3.180","volume":"29","author":"Oleck J.","year":"2016","unstructured":"Oleck J.; Kassam S.; Goldman J.D.; Commentary: Why was inhaled insulin a failure in the market? Diabetes Spectr 2016,29(3),180-184","journal-title":"Diabetes Spectr"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.clinthera.2014.06.025","volume":"36","author":"Santos Cavaiola T.","year":"2014","unstructured":"Santos Cavaiola T.; Edelman S.; Inhaled insulin: A breath of fresh air? A review of inhaled insulin. Clin Ther 2014,36(8),1275-1289","journal-title":"Clin Ther"},{"key":"ref=80","first-page":"735-741","volume":"40","author":"Goldberg T.","year":"2015","unstructured":"Goldberg T.; Wong E.; Afrezza (insulin human) inhalation powder: A new inhaled insulin for the management of type-1 or type-2 diabetes mellitus. PT, 2015,40(11),735-741"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1932296816677577","volume":"11","author":"Muchmore D.B.","year":"2017","unstructured":"Muchmore D.B.; The need for faster insulin: Problem solved? J Diabetes Sci Technol 2017,11(1),157-159","journal-title":"J Diabetes Sci Technol"},{"key":"ref=82","first-page":"OE01","volume":"11","author":"Mohanty R.R.","year":"2017","unstructured":"Mohanty R.R.; Das S.; Inhaled insulin-current direction of insulin research. J Clin Diagn Res 2017,11(4),OE01-OE02","journal-title":"J Clin Diagn Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/03007995.2020.1843423","volume":"37","author":"Piras de Oliveira C.","year":"2021","unstructured":"Piras de Oliveira C.; Mitchell B.D.; Fan L.; Garey C.; Liao B.; Bispham J.; Vint N.; Perez-Nieves M.; Hughes A.; McAuliffe-Fogarty A.; Patient perspectives on the use of half-unit insulin pens by people with type 1 diabetes: A cross-sectional observational study. Curr Med Res Opin 2021,37(1),45-51","journal-title":"Curr Med Res Opin"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"70","DOI":"10.17925\/EE.2019.15.2.70","volume":"15","author":"Zimmerman C.","year":"2019","unstructured":"Zimmerman C.; Albanese-O\u2019Neill A.; Haller M.J.; Advances in type 1 diabetes technology over the last decade. Eur Endocrinol 2019,15(2),70-76","journal-title":"Eur Endocrinol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/157488507779422374","volume":"2","author":"Jadhav K.R.","year":"2007","unstructured":"Jadhav K.R.; Gambhire M.N.; Shaikh I.M.; Kadam V.J.; Pisal S.S.; Nasal drug delivery system-factors affecting and applications. Curr Drug Ther 2007,2(1),27-38","journal-title":"Curr Drug Ther"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5530\/rjps.2012.1.4","volume":"2","author":"Deshpande T.","year":"2012","unstructured":"Deshpande T.; Masareddy R.; Patil A.; Nasal drug delivery-a review. RGUHS J Pharm Sci 2012,2(1),24-37","journal-title":"RGUHS J Pharm Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:PHAR.0000026823.82950.ff","volume":"26","author":"T\u00fcrker S.","year":"2004","unstructured":"T\u00fcrker S.; Onur E.; \u00d3zer Y.; Nasal route and drug delivery systems. Pharm World Sci 2004,26(3),137-142","journal-title":"Pharm World Sci"},{"key":"ref=88","first-page":"333","volume":"3","author":"Appasaheb P.S.","year":"2013","unstructured":"Appasaheb P.S.; Manohar S.D.; Bhanudas S.R.; Anjaneri N.; A review on intranasal drug delivery system. J Adv Pharm Edu Res 2013,3(4),333-346","journal-title":"J Adv Pharm Edu Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1177\/193229680800200613","volume":"2","author":"Leary A.C.","year":"2008","unstructured":"Leary A.C.; Dowling M.; Cussen K.; O\u2019Brien J.; Stote R.M.; Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: Infuence of the nasal cycle. J Diabetes Sci Technol 2008,2(6),1054-1060","journal-title":"J Diabetes Sci Technol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","volume":"27","author":"Freiherr J.","year":"2013","unstructured":"Freiherr J.; Hallschmid M.; Frey W.H.; Br\u00fcnner Y.F.; Chapman C.D.; H\u00f6lscher C.; Craft S.; De Felice F.G.; Benedict C.; Intranasal insulin as a treatment for Alzheimer\u2019s disease: A review of basic research and clinical evidence. CNS Drugs 2013,27(7),505-514","journal-title":"CNS Drugs"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2010.08.004","volume":"148","author":"Sintov A.C.","year":"2010","unstructured":"Sintov A.C.; Levy H.V.; Botner S.; Systemic delivery of insulin via the nasal route using a new microemulsion system: In vitro and in vivo studies. J Control Release 2010,148(2),168-176","journal-title":"J Control Release"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ejpb.2007.12.001","volume":"69","author":"Jain A.K.","year":"2008","unstructured":"Jain A.K.; Khar R.K.; Ahmed F.J.; Diwan P.V.; Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm 2008,69(2),426-435","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5958\/2231-5659.2017.00029.7","volume":"7","author":"Bhalerao R.","year":"2017","unstructured":"Bhalerao R.; Patil A.; Rishipathak D.; Kshirsagar S.; Insulin therapies: Current and future trends. Asian J Res Pharm Sci 2017,7(4),189-196","journal-title":"Asian J Res Pharm Sci"},{"key":"ref=94","first-page":"141","volume":"13","author":"Macleod J.J.R.","year":"2011","unstructured":"Macleod J.J.R.; Advances in diabetes care: Insulin. Diabetes and Primary Care 2011,13(3),141","journal-title":"Diabetes and Primary Care"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11910-007-0058-7","volume":"7","author":"Whitmer R.A.","year":"2007","unstructured":"Whitmer R.A.; Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007,7(5),373-380","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"Hanson L.R.","year":"2008","unstructured":"Hanson L.R.; Frey W.H.; Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008,9(Suppl. 3),S5","journal-title":"BMC Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2019-0013","volume":"10","author":"Schwarz B.","year":"2019","unstructured":"Schwarz B.; Merkel O.M.; Nose-to-brain delivery of biologics. Ther Deliv 2019,10(4)","journal-title":"Ther Deliv"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jalz.2013.12.006","volume":"10","author":"H\u00f6lscher C.","year":"2014","unstructured":"H\u00f6lscher C.; First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer\u2019s disease. Alzheimers Dement 2014,10(1)(Suppl.),S33-S37","journal-title":"Alzheimers Dement"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/03639041003657295","volume":"36","author":"Paudel K.S.","year":"2010","unstructured":"Paudel K.S.; Hammell D.C.; Agu R.U.; Valiveti S.; Stinchcomb A.L.; Cannabidiol bioavailability after nasal and transdermal application: Effect of permeation enhancers. Drug Dev Ind Pharm 2010,36(9),1088-1097","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"e17219","DOI":"10.7759\/cureus.17219","volume":"13","author":"Gaddam M.","year":"2021","unstructured":"Gaddam M.; Singh A.; Jain N.; Avanthika C.; Jhaveri S.; De la Hoz I.; Sanka S.; Goli S.R.; A comprehensive review of intranasal insulin and its effect on the cognitive function of diabetics. Cureus 2021,13(8),e17219","journal-title":"Cureus"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40263-020-00781-x","volume":"35","author":"Hallschmid M.","year":"2021","unstructured":"Hallschmid M.; Intranasal insulin for Alzheimer\u2019s disease. CNS Drugs 2021,35(1),21-37","journal-title":"CNS Drugs"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"e12934","DOI":"10.1111\/jne.12934","volume":"33","author":"Hallschmid M.","year":"2021","unstructured":"Hallschmid M.; Intranasal insulin. J Neuroendocrinol 2021,33(4),e12934","journal-title":"J Neuroendocrinol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s11011-021-00727-2","volume":"36","author":"Gwizdala K.L.","year":"2021","unstructured":"Gwizdala K.L.; Ferguson D.P.; Kovan J.; Novak V.; Pontifex M.B.; Placebo controlled phase II clinical trial: Safety and efficacy of combining intranasal insulin and acute exercise. Metab Brain Dis 2021,36(6),1289-1303","journal-title":"Metab Brain Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"Craft S.","year":"2020","unstructured":"Craft S.; Raman R.; Chow T.W.; Rafii M.S.; Sun C.K.; Rissman R.A.; Donohue M.C.; Brewer J.B.; Jenkins C.; Harless K.; Gessert D.; Aisen P.S.; Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: A randomized clinical trial. JAMA Neurol 2020,77(9),1099-1109","journal-title":"JAMA Neurol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijpharm.2011.05.060","volume":"415","author":"Chen C.C.","year":"2011","unstructured":"Chen C.C.; Fang C.L.; Al-Suwayeh S.A.; Leu Y.L.; Fang J.Y.; Transdermal delivery of selegiline from alginate-Pluronic composite thermogels. Int J Pharm 2011,415(1-2),119-128","journal-title":"Int J Pharm"},{"key":"ref=106","first-page":"1303","volume":"2","author":"Verma S.","year":"2011","unstructured":"Verma S.; Kaul M.; Rawat A.; Saini S.; An overview on buccal drug delivery system. Int J Pharm Sci Res 2011,2(6),1303","journal-title":"Int J Pharm Sci Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/jps.10505","volume":"92","author":"Nicolazzo J.A.","year":"2003","unstructured":"Nicolazzo J.A.; Reed B.L.; Finnin B.C.; The effect of various in vitro conditions on the permeability characteristics of the buccal mucosa. J Pharm Sci 2003,92(12),2399-2410","journal-title":"J Pharm Sci"},{"key":"ref=108","first-page":"171","volume":"3","author":"Puratchikody A.","year":"2011","unstructured":"Puratchikody A.; Prasanth V.V.; Mathew S.T.; Kumar A.; Buccal drug delivery: Past, present and future-a review. Int J Drug Deliv 2011,3(2),171","journal-title":"Int J Drug Deliv"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"388","DOI":"10.18433\/jpps30528","volume":"22","author":"Uddin M.N.","year":"2019","unstructured":"Uddin M.N.; Allon A.; Roni M.A.; Kouzi S.; Overview and future potential of fast dissolving buccal films as drug delivery system for vaccines. J Pharm Pharm Sci 2019,22(1),388-406","journal-title":"J Pharm Pharm Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0378-5173(01)00934-6","volume":"233","author":"Walker G.F.","year":"2002","unstructured":"Walker G.F.; Langoth N.; Bernkop-Schn\u00fcrch A.; Peptidase activity on the surface of the porcine buccal mucosa. Int J Pharm 2002,233(1-2),141-147","journal-title":"Int J Pharm"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0378-5173(89)90316-5","volume":"53","author":"Aungst B.J.","year":"1989","unstructured":"Aungst B.J.; Rogers N.J.; Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery. Int J Pharm 1989,53(3),227-235","journal-title":"Int J Pharm"},{"key":"ref=112","first-page":"80","volume":"5","author":"Rao N.R.","year":"2013","unstructured":"Rao N.R.; Shravani B.; Reddy M.S.; Overview on buccal drug delivery systems. J Pharm Sci Res 2013,5(4),80","journal-title":"J Pharm Sci Res"},{"key":"ref=113","first-page":"11","volume":"4","author":"Reddy J.R.K.","year":"2016","unstructured":"Reddy J.R.K.; Formulation and Ev. Pharm Res 2016,4(1),11-17","journal-title":"Pharm Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/btm2.10015","volume":"1","author":"Banerjee A.","year":"2016","unstructured":"Banerjee A.; Lee J.; Mitragotri S.; Intestinal mucoadhesive devices for oral delivery of insulin. Bioeng Transl Med 2016,1(3),338-346","journal-title":"Bioeng Transl Med"},{"key":"ref=115","first-page":"210","volume":"141","author":"Hosny E.A.","year":"2002","unstructured":"Hosny E.A.; Elkheshen S.A.; Saleh S.I.; Buccoadhesive tablets for insulin delivery: In-vitro and in-vivo studies. Boll Chim Farm 2002,141(3),210-217","journal-title":"Boll Chim Farm"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1517\/17425247.5.9.1047","volume":"5","author":"Bernstein G.","year":"2008","unstructured":"Bernstein G.; Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv 2008,5(9),1047-1055","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"pp. 423-436","DOI":"10.1007\/978-1-4614-9524-6_19","author":"Bansal M.","year":"2014","unstructured":"Bansal M.; Bansal S.; Kumria R.; The RapidMist\u2122 System for Buccal Delivery of Insulin. In: das Neves, J.; Sarmento, B.; Eds. Mucosal Delivery of Biopharmaceuticals; Springer: Boston, MA, 2014,pp. 423-436"},{"key":"ref=118","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-10939-8","author":"Crasto W.","year":"2016","unstructured":"Crasto W.; Jarvis J.; Davies M.J.; Handbook of Insulin Therapies 2016","journal-title":"Handbook of Insulin Therapies"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00125-020-05375-2","volume":"64","author":"Beran D.","year":"2021","unstructured":"Beran D.; Lazo-Porras M.; Mba C.M.; Mbanya J.C.; A global perspective on the issue of access to insulin. Diabetologia 2021,64(5),954-962","journal-title":"Diabetologia"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/193229680900300323","volume":"3","author":"Heinemann L.","year":"2009","unstructured":"Heinemann L.; Jacques Y.; Oral insulin and buccal insulin: A critical reappraisal. J Diabetes Sci Technol 2009,3(3),568-584","journal-title":"J Diabetes Sci Technol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.2147\/IJN.S318092","volume":"16","author":"Bashyal S.","year":"2021","unstructured":"Bashyal S.; Seo J.E.; Keum T.; Noh G.; Lamichhane S.; Kim J.H.; Kim C.H.; Choi Y.W.; Lee S.; Facilitated buccal insulin delivery via hydrophobic ion-pairing approach: In vitro and ex vivo evaluation. Int J Nanomedicine 2021,16,4677-4691","journal-title":"Int J Nanomedicine"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/pharmaceutics13040565","volume":"13","author":"Bashyal S.","year":"2021","unstructured":"Bashyal S.; Seo J.E.; Keum T.; Noh G.; Lamichhane S.; Lee S.; Development, characterization, and ex vivo assessment of elastic liposomes for enhancing the buccal delivery of insulin. Pharmaceutics 2021,13(4),565","journal-title":"Pharmaceutics"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jpurol.2013.12.017","volume":"10","author":"Gleason J.M.","year":"2014","unstructured":"Gleason J.M.; Daniels C.; Williams K.; Varghese A.; Koyle M.A.; B\u00e4gli D.J.; Pippi Salle J.L.; Lorenzo A.J.; Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: An attractive, well tolerated alternative form of administration. J Pediatr Urol 2014,10(4),753-757","journal-title":"J Pediatr Urol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1517\/17425247.2.3.533","volume":"2","author":"Schuetz Y.B.","year":"2005","unstructured":"Schuetz Y.B.; Naik A.; Guy R.H.; Kalia Y.N.; Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2005,2(3),533-548","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=125","first-page":"66","volume":"2","author":"Shingade G.M.","year":"2012","unstructured":"Shingade G.M.; Review on: Recent trend on transdermal drug delivery system. J Drug Deliv Ther 2012,2(1),66-75","journal-title":"J Drug Deliv Ther"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/pharmaceutics13010100","volume":"13","author":"Ahad A.","year":"2021","unstructured":"Ahad A.; Raish M.; Bin Jardan Y.A.; Al-Mohizea A.M.; Al-Jenoobi F.I.; Delivery of insulin via skin route for the management of diabetes mellitus: Approaches for breaching the obstacles. Pharmaceutics 2021,13(1),100","journal-title":"Pharmaceutics"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"Prausnitz M.R.","year":"2008","unstructured":"Prausnitz M.R.; Langer R.; Transdermal drug delivery. Nat Biotechnol 2008,26(11),1261-1268","journal-title":"Nat Biotechnol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/1753-0407.12538","volume":"9","author":"Sibiya N.","year":"2017","unstructured":"Sibiya N.; Ngubane P.; Mabandla M.; Cardioprotective effects of pectin-insulin patch in streptozotocin-induced diabetic rats. J Diabetes 2017,9(12),1073-1081","journal-title":"J Diabetes"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1773-2247(14)50041-X","volume":"24","author":"Ita K.B.","year":"2014","unstructured":"Ita K.B.; Transdermal drug delivery: Progress and challenges. J Drug Deliv Sci Technol 2014,24(3),245-250","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"169","DOI":"10.15171\/apb.2018.021","volume":"8","author":"Haque T.","year":"2018","unstructured":"Haque T.; Talukder M.M.U.; Chemical enhancer: A simplistic way to modulate barrier function of the stratum corneum. Adv Pharm Bull 2018,8(2),169-179","journal-title":"Adv Pharm Bull"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s11095-012-0946-7","volume":"30","author":"Andrews S.N.","year":"2013","unstructured":"Andrews S.N.; Jeong E.; Prausnitz M.R.; Transdermal delivery of molecules is limited by full epidermis, not just stratum corneum. Pharm Res 2013,30(4),1099-1109","journal-title":"Pharm Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4155\/tde.12.10","volume":"3","author":"G\u00f3mez C.","year":"2012","unstructured":"G\u00f3mez C.; Benito M.; Teij\u00f3n J.M.; Blanco M.D.; Novel methods and devices to enhance transdermal drug delivery: The importance of laser radiation in transdermal drug delivery. Ther Deliv 2012,3(3),373-388","journal-title":"Ther Deliv"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1159\/000480395","volume":"42","author":"Sibiya N.","year":"2017","unstructured":"Sibiya N.; Ngubane P.; Mabandla M.; The ameliorative effect of pectin-insulin patch on renal injury in streptozotocin-induced diabetic rats. Kidney Blood Press Res 2017,42(3),530-540","journal-title":"Kidney Blood Press Res"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1139\/cjpp-2018-0415","volume":"96","author":"Sibiya N.","year":"2018","unstructured":"Sibiya N.; Mabandla M.; The pectin-insulin patch application prevents the onset of peripheral neuropathy-like symptoms in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 2018,96(12),1286-1292","journal-title":"Can J Physiol Pharmacol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"e101461","DOI":"10.1371\/journal.pone.0101461","volume":"9","author":"Hadebe S.I.","year":"2014","unstructured":"Hadebe S.I.; Ngubane P.S.; Serumula M.R.; Musabayane C.T.; Transdermal delivery of insulin by amidated pectin hydrogel matrix patch in streptozotocin-induced diabetic rats: Effects on some selected metabolic parameters. PLoS One 2014,9(7),e101461","journal-title":"PLoS One"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1039\/C9NH00576E","volume":"5","author":"Pagneux Q.","year":"2020","unstructured":"Pagneux Q.; Ye R.; Chengnan L.; Barras A.; Hennuyer N.; Staels B.; Caina D.; Osses J.I.A.; Abderrahmani A.; Plaisance V.; Pawlowski V.; Boukherroub R.; Melinte S.; Szunerits S.; Electrothermal patches driving the transdermal delivery of insulin. Nanoscale Horiz 2020,5(4),663-670","journal-title":"Nanoscale Horiz"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"119416","DOI":"10.1016\/j.ijpharm.2020.119416","volume":"584","author":"Harjoh N.","year":"2020","unstructured":"Harjoh N.; Wong T.W.; Caramella C.; Transdermal insulin delivery with microwave and fatty acids as permeation enhancers. Int J Pharm 2020,584,119416","journal-title":"Int J Pharm"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"719905","DOI":"10.3389\/fphar.2021.719905","volume":"12","author":"Zhang N.","year":"2021","unstructured":"Zhang N.; Zhou X.; Liu L.; Zhao L.; Xie H.; Yang Z.; Dissolving polymer microneedles for transdermal delivery of insulin. Front Pharmacol 2021,12,719905","journal-title":"Front Pharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4161\/gmic.23867","volume":"4","author":"Zhang Q.","year":"2013","unstructured":"Zhang Q.; Widmer G.; Tzipori S.; A pig model of the human gastrointestinal tract. Gut Microbes 2013,4(3),193-200","journal-title":"Gut Microbes"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00125-018-4763-3","volume":"62","author":"Patterson C.C.","year":"2019","unstructured":"Patterson C.C.; Harjutsalo V.; Rosenbauer J.; Neu A.; Cinek O.; Skrivarhaug T.; Rami-Merhar B.; Soltesz G.; Svensson J.; Parslow R.C.; Castell C.; Schoenle E.J.; Bingley P.J.; Dahlquist G.; Jarosz-Chobot P.K.; Mar\u010diulionyt\u0117 D.; Roche, E.F.; Rothe, U.; Bratina, N.; Ionescu-Tirgoviste, C.; Weets, I.; Kocova, M.; Cherubini, V.; Rojnic Putarek, N.; deBeaufort, C.E.; Samardzic, M.; Green, A. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: A multicentre prospective registration study. Diabetologia 2019,62(3),408-417","journal-title":"Diabetologia"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2217\/cer-2020-0273","volume":"10","author":"Godman B.","year":"2021","unstructured":"Godman B.; Fadare J.; Kwon H.Y.; Dias C.Z.; Kurdi A.; Dias God\u00f3i I.P.; Kibuule D.; Hoxha I.; Opanga S.; Saleem Z.; Bochenek T.; Markovi\u0107-Pekovi\u0107 V.; Mardare, I.; Kalungia, A.C.; Campbell, S.; Allocati, E.; Pisana, A.; Martin, A.P.; Meyer, J.C. Evidence-based public policy making for medicines across countries: Findings and implications for the future. J Comp Eff Res 2021,10(12),1019-1052","journal-title":"J Comp Eff Res"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"143","DOI":"10.17925\/EE.2020.16.2.143","volume":"16","author":"Sharma S.K.","year":"2020","unstructured":"Sharma S.K.; Kant R.; Kalra S.; Bishnoi R.; Prevalence of primary non-adherence with insulin and barriers to insulin initiation in patients with type 2 diabetes mellitus - an exploratory study in a tertiary care teaching public hospital. Eur Endocrinol 2020,16(2),143-147","journal-title":"Eur Endocrinol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jdiacomp.2019.04.016","volume":"33","author":"Hayfron-Benjamin C.","year":"2019","unstructured":"Hayfron-Benjamin C.; van den Born B.J.; Maitland-van der Zee A.H.; Amoah A.G.B.; Meeks K.A.C.; Klipstein-Grobusch K.; Bahendeka S.; Spranger J.; Danquah I.; Mockenhaupt F.; Beune E.; Smeeth L.; Agyemang C.; Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: The RODAM study. J Diabetes Complications 2019,33(8),572-578","journal-title":"J Diabetes Complications"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"e13336","DOI":"10.1111\/obr.13336","volume":"22","author":"Wong J.","year":"2021","unstructured":"Wong J.; Chan K.Y.; Lo K.; Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: A meta-analysis. Obes Rev 2021,22(12),e13336","journal-title":"Obes Rev"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/dom.12665","volume":"18","author":"Patorno E.","year":"2016","unstructured":"Patorno E.; Everett B.M.; Goldfine A.B.; Glynn R.J.; Liu J.; Gopalakrishnan C.; Kim S.C.; Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists via other antidiabetic drugs in routine care: A cohort study. Diabetes Obes Metab 2016,18(8),755-765","journal-title":"Diabetes Obes Metab"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.yjmcc.2015.12.026","volume":"91","author":"Kubota A.","year":"2016","unstructured":"Kubota A.; Takano H.; Wang H.; Hasegawa H.; Tadokoro H.; Hirose M.; Kobara Y.; Yamada-Inagawa T.; Komuro I.; Kobayashi Y.; DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. J Mol Cell Cardiol 2016,91,72-80","journal-title":"J Mol Cell Cardiol"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220531101203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205430\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201819666220531101203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T06:09:57Z","timestamp":1727330997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205430\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":146,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201819666220531101203","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}